Close Menu

NEW YORK (360Dx) – A team led by researchers from IBM have identified a plasma protein signature that predicts cerebrospinal fluid (CSF) levels of the Alzheimer's disease marker amyloid-β42.

Part of a growing body of research into blood-based biomarkers for Alzheimer's disease, the study, published this week in Nature Scientific Reports, adds to the evidence that blood tests could prove useful alternatives to the CSF and PET imaging-based tests currently used to assess brain amyloid levels.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.